Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Efficacy Data
-
Can we present non-significant (N/S) efficacy data in an APS that is included in the Product Monograph (Part II: Clinical trials section)? Does it matter if it’s a primary, secondary or exploratory endpoint? If we can present N/S efficacy data, what parameters are required in order to present these in an APS?
-
Can we present non-significant (N/S) efficacy data in an APS that is included in the Product Monograph (Part II: Clinical trials section)? Does it matter if it’s a primary, secondary or exploratory endpoint? If we can present N/S efficacy data, what parameters are required in order to present these in an APS?
